AI-Guided Bronchoscopy Using the Broncho AI Navigator
Real-Time AI-Guided Bronchoscopy: A Two-Phase Clinical Study Evaluating Usability and Impact on Procedural Performance Metrics of the Broncho AI Navigator
This clinical investigation evaluates the Ambu Broncho AI Navigator, an investigational software system designed to provide real-time navigational support during bronchoscopy. The system uses artificial intelligence to identify and display airway anatomy during procedures and to help bronchoscopists track which airway segments have been examined.
The study is conducted at Odense University Hospital and consists of two phases. In Phase 2a, experienced bronchoscopists use the system during routine bronchoscopies to evaluate and optimize technical settings and usability. For this phase 45 patients will be enrolled. In Phase 2b, bronchoscopies are randomized (1:1) to be performed with or without the Broncho AI Navigator to evaluate the impact of AI guidance on procedural performance. For this phase 108 patients will be enrolled.
Adult patients undergoing elective bronchoscopy are enrolled, while the primary study subjects are the bronchoscopists performing the procedures. The study evaluates whether use of the Broncho AI Navigator improves bronchoscopy performance by increasing diagnostic completeness, improving structured progression through the bronchial tree, and reducing procedure time. The findings will support further development and future validation of the Broncho AI Navigator in clinical practice.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Christian Borbjerg Laursen, MD
- 電話番号:+45 3023 1114
- メール:Christian.b.laursen@rsyd.dk
研究場所
-
-
Region Syddanmark
-
Odense、Region Syddanmark、デンマーク、5000
- 募集
- Odense University Hospital
-
コンタクト:
- Christian Borbjerg Laursen, MD
- 電話番号:+45 3023 1114
- メール:Christian.b.laursen@rsyd.dk
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Phase 2a (System calibration):
Inclusion Criteria:
- Patients indicated for bronchoscopy of central airways as per standard of care.
- Patients with an age of 18 years or above.
Exclusion Criteria:
- Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
- Patients who are unable or unwilling to give informed consent.
- Patients with highly abnormal lung anatomy.
- Patients with conditions which significantly impact the visual appearance of the airway tissue, such as heavy bleeding, secretions, or inflammation.
- Patients who are pregnant or breastfeeding
- Patients previously enrolled in either phase 2a
Phase 2b (Randomized study):
Inclusion Criteria:
- Patients indicated for bronchoscopy of central airways as per standard of care.
- Patients with an age of 18 years or above.
Exclusion Criteria:
- Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
- Patients who are unable or unwilling to give informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Broncho AI Navigator
|
The Broncho AI Navigator is an investigational software device designed to provide real-time navigational support during bronchoscopy. The system analyzes live bronchoscopy video using artificial intelligence to identify anatomical landmarks and bronchial segments and displays this information on a monitor to assist navigation through the tracheobronchial tree. The software is evaluated as an adjunct to standard bronchoscopy procedures. |
|
介入なし:Standard Bronchoscopy
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diagnostic completeness
時間枠:At the time of the procedure
|
Diagnostic completeness is defined as the bronchoscopist's ability to visualize all available tertiary bronchial segments (RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, LB1+2, LB3, LB4, LB5, LB6, LB8, LB9, and LB10) using the bronchoscope. For the purpose of this investigation, a procedure is considered fully diagnostically complete (score of 1) if all tertiary segments are visualized. If any segments are not visualized, the procedure is deemed diagnostically incomplete (score of 0). |
At the time of the procedure
|
|
Structured progression
時間枠:At the time of the procedure
|
The structured progression outcome is scored between 0 and 18, with 18 indicating 18 correct progressions. A point is awarded when the bronchoscopist visualizes one segment and then immediately proceeds to the succeeding segment (e.g., visualizing RB1 followed by RB2 results in a point, whereas RB2 followed by RB1 does not). |
At the time of the procedure
|
|
Procedure time
時間枠:At the time of the procedure
|
Procedure time is defined as the duration required for the bronchoscopist to visualize all 18 segments, starting from the visualization of the first segment to the last. |
At the time of the procedure
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CIS-030
- 16-0300-55 (その他の識別子:Medical Research Ethics Committees (MREC), Denmark)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be made publicly available. The study includes clinical procedure data and video recordings collected for medical device development and evaluation. Data contain information that could increase the risk of re-identification, and sharing is restricted to protect participant privacy and confidentiality in accordance with applicable data protection requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。